AIM ImmunoTech (NYSE:AIM) Trading 3.9% Higher – Should You Buy?

AIM ImmunoTech Inc. (NYSE:AIM)’s stock price traded up 3.9% during mid-day trading on Tuesday . The stock traded as high as $0.25 and last traded at $0.24. 239,357 shares traded hands during trading, a decline of 5% from the average session volume of 252,331 shares. The stock had previously closed at $0.23.

Analysts Set New Price Targets

AIM has been the topic of several recent research reports. Maxim Group cut their target price on shares of AIM ImmunoTech from $2.00 to $1.00 and set a “buy” rating on the stock in a research report on Tuesday, October 22nd. Ascendiant Capital Markets reduced their price target on AIM ImmunoTech from $5.25 to $5.00 and set a “buy” rating on the stock in a research report on Tuesday, September 3rd.

AIM ImmunoTech Stock Up 8.7 %

The company has a quick ratio of 1.17, a current ratio of 1.17 and a debt-to-equity ratio of 0.05. The stock has a 50 day simple moving average of $0.27 and a 200 day simple moving average of $0.34. The stock has a market cap of $16.75 million, a price-to-earnings ratio of -0.44 and a beta of -0.36.

AIM ImmunoTech (NYSE:AIM) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.03) earnings per share (EPS) for the quarter. AIM ImmunoTech had a negative net margin of 13,952.74% and a negative return on equity of 269.04%. The business had revenue of $0.05 million for the quarter. As a group, analysts expect that AIM ImmunoTech Inc. will post -0.35 earnings per share for the current fiscal year.

Institutional Trading of AIM ImmunoTech

An institutional investor recently bought a new position in AIM ImmunoTech stock. Armistice Capital LLC acquired a new position in AIM ImmunoTech Inc. (NYSE:AIM) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 4,078,000 shares of the company’s stock, valued at approximately $1,520,000. Armistice Capital LLC owned about 7.92% of AIM ImmunoTech at the end of the most recent quarter. Institutional investors own 12.02% of the company’s stock.

About AIM ImmunoTech

AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).